Feasibility and Efficacy of Stereotactic Ablative Radiotherapy for Barcelona Clinic Liver Cancer-C Stage Hepatocellular Carcinoma

Bae, Sun Hyun; Kim, Misook; Cho, Chul Koo; Kim, Kum Bae; Lee, Dong Han; Han, Chul Ju; Park, Su Cheol; Kim, Young Han

doi:10.3346/jkms.2013.28.2.213

Cited by 40 publications

(45 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AEs are major issues in SBRT for locally advanced HCC. Bujold et al and Bae et al reported that SBRT-induced toxicity ≥ grade 3 was seen in 14-30% of HCCs 30,31 . In the particle radiotherapy for locally advanced HCC, the incident rate of severe toxicities was found to be low, but toxicities did occur [32][33][34] .…”

Section: Discussionmentioning

confidence: 99%

Preoperative Stereotactic Body Radiotherapy to Portal Vein Tumour Thrombus in Hepatocellular Carcinoma: Clinical and Pathological Analysis

Kishi

Kanayama

Hirata

et al. 2020

Sci Rep

View full text Add to dashboard Cite

& teruki teshima 1 the prognosis of hepatocellular carcinoma (Hcc) with portal vein tumour thrombus (pVtt) is poor. We conducted a prospective study to evaluate the efficacy and safety of tri-modality therapy, including preoperative stereotactic body radiotherapy (SBRt) and surgery, followed by hepatic arterial infusion chemotherapy (HAic) in Hcc patients with pVtt. in this report, we investigated the pathology of the irradiated PVTT specimen in resected cases and SBRT-related acute toxicity. A total of 8 HCC patients with PVTT received preoperative SBRT targeting the PVTT at a dose of 48 Gy in 4 fractions at our institute from 2012 to 2016. Of the eight patients, six underwent surgery, while the remaining two did not because of disease progression. At the pathological examination, all patients' irradiated pVtt specimens showed necrotic tissue, and three of six patients showed complete pathological response. Two patients showed 30% necrosis with high degeneration and one patient, with 30% necrosis without degeneration, was the only recurrent case found during the follow-up period (median: 22.5, range: 5.9-49.6 months). No SBRT-related acute toxicity worse than grade 2 was observed from SBRT to surgery. In conclusion, the preoperative SBRT for HCC was pathologically effective and the acute toxicities were tolerable.

show abstract

Section: Discussionmentioning

confidence: 99%

Preoperative Stereotactic Body Radiotherapy to Portal Vein Tumour Thrombus in Hepatocellular Carcinoma: Clinical and Pathological Analysis

Kishi

Kanayama

Hirata

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Moreover, recent reports indicated that SBRT was as effective as TACE and RFA (33,34). In a previous series, SBRT provided 1-, 2-, and 3-year local control rates of 56-100%, 53-95%, and 51-92%, and 1-, 2-, and 3-year survival rates of 32-100%, 55-100%, and 21-82% for HCC, respectively (11)(12)(13)(14)(15)(16)(17)(18)(19).…”

Section: Sbrt For Primary Liver Cancersmentioning

confidence: 91%

“…Radiotherapy has also been used for palliative care in liver tumors (7)(8)(9). Modern radiotherapies, including stereotactic body radiation therapy (SBRT), intensity-modulated radiotherapy (IMRT), and particle therapies, have recently attracted increasing attention as therapeutic modalities for various malignancies and have dramatically increased the use of radiation therapy as a curative modality (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26).…”

Section: Abstract Surgical Resection Is the Standard Therapy Formentioning

confidence: 99%

Stereotactic Body Radiation Therapy for Liver Tumors: Current Status and Perspectives

Doi

Beppu

Kitajima

et al. 2018

View full text Add to dashboard Cite

Surgical resection is the standard therapy for solitary primary or metastatic liver tumors. However, liver tumors are often unresectable at diagnosis and hepatectomy is invasive. Local therapies, such as radiofrequency ablation, are used instead, which can be challenging. Recent advances in modern radiotherapy, including stereotactic body radiation therapy (SBRT), have increased the use of radiotherapy as a curative modality. SBRT delivers ablative high doses of irradiation in small volumes. SBRT for liver tumors provided local control with potential survival benefits in patients with inoperable status. However, the following issues remain: primary vs. metastatic liver cancers; SBRT-related toxicity and prevention; pathological features of liver cancers; and potential SBRT strategies. We summarized a literature review to summarize the effectiveness of SBRT and patient tolerance and present the current status and future perspective of SBRT for liver tumors. SBRT is a potential game changer for multimodal therapy.

show abstract

“…The 1-and 3-year local control rates were 69% and 51%, respectively. SBRT dose of BED ≥80 Gy 10 was a significant prognostic factor for survival [25].…”

Section: Rt Fractionationmentioning

confidence: 99%

How to Improve Therapeutic Ratio in Radiotherapy of HCC

2016

View full text Add to dashboard Cite

Background: During the past two decades, external-beam radiation technology has substantially changed from traditional two-dimensional to conformal three-dimensional to intensity-modulated planning and stereotactic body radiotherapy (SBRT). Summary: Modern techniques of radiotherapy (RT) are highly focused and capable of delivering an ablative dose to targeted hepatocellular carcinoma (HCC) tumors. SBRT is an option for selected patients with limited tumor volume and non-eligibility for other invasive treatments. Moreover, RT combined with a radiation sensitizer (RS) to increase the therapeutic ratio has shown promising results in select studies, prompting further investigation of this combination. With the undetermined role of RT in treatment guidelines and variation in patterns of treatment failure after RT in patient with HCC, useful biomarkers to guide RT decision-making and selection of patients are needed and emerging. Key Message: The objective of this review is to summarize the current RS with SBRT schemes and biomarkers for patient selection used to maximize the effect of RT on HCC.

show abstract

Feasibility and Efficacy of Stereotactic Ablative Radiotherapy for Barcelona Clinic Liver Cancer-C Stage Hepatocellular Carcinoma

Cited by 40 publications

References 26 publications

Preoperative Stereotactic Body Radiotherapy to Portal Vein Tumour Thrombus in Hepatocellular Carcinoma: Clinical and Pathological Analysis

Preoperative Stereotactic Body Radiotherapy to Portal Vein Tumour Thrombus in Hepatocellular Carcinoma: Clinical and Pathological Analysis

Stereotactic Body Radiation Therapy for Liver Tumors: Current Status and Perspectives

How to Improve Therapeutic Ratio in Radiotherapy of HCC

Contact Info

Product

Resources

About